查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1967767

食慾抑制劑市場－全球產業規模、佔有率、趨勢、機會、預測：依給藥途徑、通路、地區和競爭格局分類，2021-2031年

Anorexiants Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration, By Distribution Channels, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球食慾抑制劑市場預計將從 2025 年的 11.4 億美元成長到 2031 年的 15.2 億美元，複合年成長率為 4.94%。

食慾抑制劑是旨在抑制食慾、促進飽足感的藥物，是治療方法肥胖及相關代謝紊亂的主要藥物。全球慢性體重疾病發生率的不斷上升是推動該市場成長的主要因素。這凸顯了除標準生活方式調整外，迫切需要有效的醫療干預措施。根據世界肥胖聯盟（WOF）2024年報告，全球約有30億人超重或肥胖，如此廣泛的盛行率凸顯了先進治療方案的緊迫性，並支撐著該領域的持續商業性成長。

市場概覽
預測期 2027-2031
市場規模：2025年 11.4億美元
市場規模：2031年 15.2億美元
複合年成長率：2026-2031年 4.94%
成長最快的細分市場 口服食慾抑制劑
最大的市場 北美洲

儘管市場前景廣闊，但產品安全和複雜的監管要求仍構成重大障礙。鑑於過去曾發生嚴重的心血管和精神副作用事件，衛生監管機構已實施嚴格的監測，導致研發週期延長和上市後監管更加嚴格。這種嚴格的監管可能會延緩創新製劑的上市，並限制患者的用藥途徑，從而對全球食慾抑制劑市場的快速發展構成重大阻礙。

市場促進因素

全球肥胖和過重率的不斷攀升是食慾抑制劑市場的主要驅動力，也因此產生了對強效藥物治療方法的迫切需求。由於僅靠改變生活方式往往不足以達到理想的減重效果，出於降低體重相關健康風險的臨床需要，醫療專業人員擴大開立食慾抑制劑處方。區域數據顯示，這種日益成長的負擔顯而易見；例如，美國疾病管制與預防中心（CDC）在2024年9月報告稱，2023年美國23個州的成人肥胖率超過35%。如此高的盛行率意味著不斷有患者尋求體重管理方案，從而保證了對現有和新型食慾抑制劑的持續需求。

同時，GLP-1受體促效劑的廣泛應用標誌著治療策略的重大變革，並極大地促進了市場收入的成長。這些先進的製劑比傳統藥物具有更強的飽足感，因此迅速被醫生和患者所接受。近期財務報告也印證了商業性影響力。禮來公司在2024年8月宣布，減肥藥Zeptbound的季度收入已達12.4億美元。為了滿足日益成長的代謝療法需求，生產商正在擴大生產規模。諾和諾德公司在2024年宣布投資41億美元擴建位於北卡羅來納州克萊頓的生產設施，這也是確保這些必需藥物長期供應的另一個舉措。

市場挑戰

嚴格的產品安全標準和相關的監管壁壘是全球食慾抑制劑市場擴張的主要障礙。監管機構對臨床試驗進行嚴格審查，以避免危險的心血管和精神副作用，這通常需要較長的研究週期和大規模的受試者群體。這種保守的策略增加了研發成本，延緩了新治療方法的商業性化上市，並大幅限制了製藥公司創造收入和利用創新成果的機會。

此外，這些監管延誤阻礙了市場有效應對日益嚴重的體重相關疾病經濟負擔的能力。 2024年，世界肥胖聯盟估計，到2035年，全球超重和肥胖造成的經濟損失將達到每年4.32兆美元。嚴格的安全標準阻礙了新配方快速上市，限制了該行業滿足這一巨大經濟需求的潛力。因此，醫療干預的迫切需求與監管核准的延誤之間的差距限制了患者的就醫途徑，並阻礙了該領域的更廣泛發展。

市場趨勢

製藥公司正積極探索更多食慾抑制劑的臨床適應症，尤其關注與肥胖相關的合併心血管疾病。透過證明體重管理藥物也有助於降低心臟病發作和中風的風險，藥廠旨在擴大醫保覆蓋範圍，並為長期處方提供依據。這一趨勢正在改變食慾抑制劑的定位，使其從單純的生活方式調節劑轉變為重要的心臟保護劑，並擴大其應用範圍，使其適用於體重指數（BMI）超過標準的患者群體。例如，2024年3月，美國食品藥物管理局（FDA）核准了Semaglutide注射液，該藥物可使同時患有心血管疾病和肥胖的成年人心血管死亡、心肌梗塞和中風的風險降低20%。

同時，市面上湧現出雙重和三重激素受體促效劑，它們作用於多種代謝途徑，從而達到優於單一激素藥物的減重效果。這些先進的在臨床實驗藥物除了模擬GLP-1外，還能模擬GIP和升糖素等激素，促進協同代謝和脂肪分解。這些多機制藥物的潛力正推動生技公司進行大規模研發，旨在超越目前的治療標準。例如，Viking Therapeutics公司在2024年2月報告稱，在其雙重促效劑VK2735的II期VENTURE試驗中，受試者在13週內平均減重高達13.1%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球食慾抑制劑市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 給藥途徑（皮下注射食慾抑制劑、口服食慾抑制劑）
    • 分銷通路（網路藥局、零售藥局、醫院藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美食慾抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲食慾抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區食慾抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲食慾抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美食慾抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球食慾抑制劑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • VIVUS LLC.
  • Arena Pharmaceuticals, Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • Currax Pharmaceuticals LLC.
  • AbbVie Inc.
  • ReShape Lifesciences Inc.
  • Ethicon Inc.（Subsidiary of Johnson & Johnson）.
  • Sanofi SA
  • Medtronic Plc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23824

The Global Anorexiants Market is projected to expand from USD 1.14 Billion in 2025 to USD 1.52 Billion by 2031, reflecting a compound annual growth rate of 4.94%. Anorexiants are pharmaceutical compounds designed to curb appetite and promote fullness, functioning as a key pharmacological treatment for obesity and associated metabolic issues. The market is primarily propelled by the rising global incidence of chronic weight disorders, which has generated a pressing need for effective medical interventions that surpass standard lifestyle changes. As reported by the World Obesity Federation in 2024, approximately 3 billion individuals worldwide were estimated to be living with overweight or obesity, a widespread prevalence that highlights the urgent necessity for advanced therapeutic solutions and supports the sector's ongoing commercial growth.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.14 Billion
Market Size 2031USD 1.52 Billion
CAGR 2026-20314.94%
Fastest Growing SegmentOral Anorexiants
Largest MarketNorth America

Despite these growth prospects, the market encounters substantial obstacles related to product safety and complex regulatory requirements. Health authorities enforce rigorous oversight, driven by past incidents of severe cardiovascular and psychiatric adverse effects, which leads to extended development timelines and rigorous post-marketing monitoring. This intense regulatory scrutiny can postpone the launch of innovative formulations and restrict patient availability, acting as a significant barrier to the rapid advancement of the global anorexiants market.

Market Driver

The rising global rates of obesity and overweight conditions serve as the primary engine for the anorexiants market, creating a strong need for potent pharmacological treatments. Because lifestyle changes frequently fail to achieve significant weight loss, the clinical necessity to lower weight-related health risks drives healthcare professionals to prescribe appetite suppressants more often. This growing burden is highlighted by regional data; for instance, the Centers for Disease Control and Prevention reported in September 2024 that 23 U.S. states had an adult obesity rate of 35 percent or higher during 2023. Such elevated prevalence ensures a consistent stream of patients seeking weight management solutions, thereby guaranteeing ongoing demand for both current and upcoming anorexiant medications.

Concurrently, the rising uptake of GLP-1 receptor agonists marks a major evolution in treatment strategies, contributing significantly to market revenue. These advanced formulations demonstrate greater efficacy in promoting satiety than earlier drugs, resulting in rapid adoption by both doctors and patients. The commercial impact is evident in recent financial reports; Eli Lilly and Company announced in August 2024 that quarterly revenue for its obesity drug Zepbound hit $1.24 billion. To meet this escalating demand for metabolic therapies, manufacturers are ramping up production, as seen with Novo Nordisk's 2024 announcement of a $4.1 billion investment to expand its manufacturing facility in Clayton, North Carolina, to secure the long-term supply of these essential medicines.

Market Challenge

Strict product safety mandates and associated regulatory barriers serve as major impediments to the Global Anorexiants Market's expansion. Regulatory bodies apply intense scrutiny during clinical trials to avoid dangerous cardiovascular and psychiatric side effects, often requiring prolonged study periods and larger participant groups. This conservative strategy increases development expenses and delays the commercial release of new treatments, effectively narrowing the window for pharmaceutical firms to generate revenue and capitalize on their innovations.

Moreover, these regulatory delays hinder the market's ability to effectively tackle the rising financial toll of weight-related conditions. The World Obesity Federation estimated in 2024 that the global economic cost of overweight and obesity is set to reach US$ 4.32 trillion per year by 2035. The inability to rapidly launch new formulations due to rigorous safety standards limits the industry's potential to meet this massive economic need. As a result, the gap between the urgent demand for medical interventions and the sluggish rate of regulatory authorization limits patient access and constrains the broader growth of the sector.

Market Trends

Pharmaceutical companies are increasingly seeking broader clinical indications for anorexiants, focusing specifically on cardiovascular comorbidities linked to obesity. By proving that weight-management medications can also lower the risk of heart attacks and strokes, manufacturers hope to gain wider insurance coverage and validate long-term prescription. This trend repositions anorexiants from lifestyle enhancements to vital cardioprotective treatments, expanding the patient pool beyond just BMI requirements. For example, the U.S. Food and Drug Administration approved semaglutide injection in March 2024 to decrease the risk of cardiovascular death, heart attack, and stroke by 20 percent in adults with both established cardiovascular disease and obesity.

At the same time, the market is seeing the rise of dual and triple hormone receptor agonists that influence multiple metabolic pathways to deliver weight loss results superior to single-hormone drugs. These advanced investigational treatments mimic hormones like GIP and glucagon alongside GLP-1, thereby improving metabolic synergy and fat breakdown. The promise of these multi-mechanism drugs is fueling significant research and development among biotechnology companies aiming to surpass current care standards. Illustrating this potential, Viking Therapeutics reported in February 2024 that patients in the Phase 2 VENTURE trial for the dual agonist VK2735 achieved a mean weight reduction of up to 13.1 percent after 13 weeks.

Key Market Players

  • VIVUS LLC.
  • Arena Pharmaceuticals, Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • Currax Pharmaceuticals LLC.
  • AbbVie Inc.
  • ReShape Lifesciences Inc.
  • Ethicon Inc. (Subsidiary of Johnson & Johnson).
  • Sanofi S.A.
  • Medtronic Plc.

Report Scope

In this report, the Global Anorexiants Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anorexiants Market, By Route of Administration

  • Subcutaneous Anorexiants
  • Oral Anorexiants

Anorexiants Market, By Distribution Channels

  • Online Pharmacy
  • Retail Pharmacy
  • Hospital Pharmacy

Anorexiants Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anorexiants Market.

Available Customizations:

Global Anorexiants Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anorexiants Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Route of Administration (Subcutaneous Anorexiants, Oral Anorexiants)
    • 5.2.2. By Distribution Channels (Online Pharmacy, Retail Pharmacy, Hospital Pharmacy)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Anorexiants Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Route of Administration
    • 6.2.2. By Distribution Channels
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Anorexiants Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Route of Administration
        • 6.3.1.2.2. By Distribution Channels
    • 6.3.2. Canada Anorexiants Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Route of Administration
        • 6.3.2.2.2. By Distribution Channels
    • 6.3.3. Mexico Anorexiants Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Route of Administration
        • 6.3.3.2.2. By Distribution Channels

7. Europe Anorexiants Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Route of Administration
    • 7.2.2. By Distribution Channels
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Anorexiants Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Route of Administration
        • 7.3.1.2.2. By Distribution Channels
    • 7.3.2. France Anorexiants Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Route of Administration
        • 7.3.2.2.2. By Distribution Channels
    • 7.3.3. United Kingdom Anorexiants Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Route of Administration
        • 7.3.3.2.2. By Distribution Channels
    • 7.3.4. Italy Anorexiants Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Route of Administration
        • 7.3.4.2.2. By Distribution Channels
    • 7.3.5. Spain Anorexiants Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Route of Administration
        • 7.3.5.2.2. By Distribution Channels

8. Asia Pacific Anorexiants Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Route of Administration
    • 8.2.2. By Distribution Channels
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Anorexiants Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Route of Administration
        • 8.3.1.2.2. By Distribution Channels
    • 8.3.2. India Anorexiants Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Route of Administration
        • 8.3.2.2.2. By Distribution Channels
    • 8.3.3. Japan Anorexiants Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Route of Administration
        • 8.3.3.2.2. By Distribution Channels
    • 8.3.4. South Korea Anorexiants Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Route of Administration
        • 8.3.4.2.2. By Distribution Channels
    • 8.3.5. Australia Anorexiants Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Route of Administration
        • 8.3.5.2.2. By Distribution Channels

9. Middle East & Africa Anorexiants Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Route of Administration
    • 9.2.2. By Distribution Channels
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Anorexiants Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Route of Administration
        • 9.3.1.2.2. By Distribution Channels
    • 9.3.2. UAE Anorexiants Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Route of Administration
        • 9.3.2.2.2. By Distribution Channels
    • 9.3.3. South Africa Anorexiants Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Route of Administration
        • 9.3.3.2.2. By Distribution Channels

10. South America Anorexiants Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Route of Administration
    • 10.2.2. By Distribution Channels
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Anorexiants Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Route of Administration
        • 10.3.1.2.2. By Distribution Channels
    • 10.3.2. Colombia Anorexiants Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Route of Administration
        • 10.3.2.2.2. By Distribution Channels
    • 10.3.3. Argentina Anorexiants Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Route of Administration
        • 10.3.3.2.2. By Distribution Channels

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Anorexiants Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. VIVUS LLC.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Arena Pharmaceuticals, Ltd.
  • 15.3. F. Hoffmann-La Roche Ltd.
  • 15.4. Novo Nordisk A/S
  • 15.5. Currax Pharmaceuticals LLC.
  • 15.6. AbbVie Inc.
  • 15.7. ReShape Lifesciences Inc.
  • 15.8. Ethicon Inc. (Subsidiary of Johnson & Johnson).
  • 15.9. Sanofi S.A.
  • 15.10. Medtronic Plc.

16. Strategic Recommendations

17. About Us & Disclaimer